NCT06020703

Brief Summary

Researchers are doing this study to find out if a high fermented food diet is tolerable, and if it will help improve quality of life after surviving a critical illness, including severe COVID-19, by promoting gut health recovery and decreasing gut inflammation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Feb 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Feb 2024Dec 2026

First Submitted

Initial submission to the registry

August 23, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 1, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

February 26, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

January 8, 2026

Status Verified

January 1, 2026

Enrollment Period

2.1 years

First QC Date

August 23, 2023

Last Update Submit

January 6, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Feasibility of high fermented food diet among critical illness survivors

    20 critical illness survivors assigned to the intervention arm will tolerate high fermented food diet on 75% of the study days or more

    12 weeks

  • gut microbiome diversity

    assessed using Shannon index

    Baseline, 12 weeks

Secondary Outcomes (5)

  • Change in inflammatory cytokines

    Baseline, 12 weeks

  • Symptoms of anxiety and depression

    Baseline, 12 weeks

  • Cognitive Assessment

    Baseline, 12 weeks

  • Self-Reported quality of life

    Baseline, 12 weeks

  • symptoms of acute stress/PTSD

    Baseline, 12 weeks

Study Arms (2)

Fermented Foods Diet

EXPERIMENTAL

Subjects will incorporate fermented food into their diet.

Behavioral: Fermented Food Diet

Normal Diet

NO INTERVENTION

Subjects will continue their regular diet.

Interventions

Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.

Fermented Foods Diet

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- patients who have survived critical illness, including severe COVID, and are at risk for mental health morbidity/long COVID (spent \>48 hours in the ICU or had COVID requiring ICU stay) who have a smartphone, are enrolled into the Mayo PICS clinic, and have at least one PICS-related impairment. Cognitive impairment, if present, has to be in the mild range to ensure patient can provide consent and follow study instructions

You may not qualify if:

  • \- History of dementia, mental retardation, psychotic disorders such as schizophrenia, patients not expected to survive the hospital stay or non-English speaking, participants not able to tolerate foods by mouth or those with potential contraindications to such diet (chronically immunosuppressed including organ transplant recipients; those with neutropenia or currently undergoing chemotherapy, those taking Monoamine oxidase inhibitors).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States

RECRUITING

MeSH Terms

Conditions

Critical IllnessCOVID-19Cognitive DysfunctionMuscle WeaknessDysbiosis

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesCognition DisordersNeurocognitive DisordersMental DisordersMuscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and Symptoms

Study Officials

  • Lioudmila Karnatovskaia, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 23, 2023

First Posted

September 1, 2023

Study Start

February 26, 2024

Primary Completion

April 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

January 8, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations